Graycell  Advisors

Quantitative Stock Model Portfolios That Perform in Bear & Bull Markets

Keeping the Bear Asleep

Your Stock Portfolio Doesn't Deserve a Mauling!
Affordable Way to Use Systematic Quantitative Model Investing

Systematic Investing manages one of the biggest threats to a portfolio - our own behavioral tendencies which constrain performance. Successful stock investing requires a disciplined system, seeking out strong ideas and managing the cauldron of emotions. We provide an affordable alternative to DIY stock investors and financial advisors to use quantitative model portfolios for systematic investing.

Why Systematic Investing


  • Market Conditions

    Market is our ultimate guide.  We invest when conditions are most favorable. This assists us to minimize damage from headwinds, and race with a tailwind.

  • Stock

    Our stock models use multiple criterias to guide us to the stocks with strong appreciation potential

  • Risk

    Built a layered risk management approach. Models guide us to invest in stocks only when all conditions are met, and scale back in tricky markets.

  • Disciplined Pursuit

    Follow the stock investing system. Don’t second-guess it. Once you’re satisfied with its performance, trust the system.

More on Approach

Your Free Monthly Stock Pick!

We value your privacy and would never share

The Way it Works

  • 1


    Check the newsletter products

  • 2


    Pick what fits your interest & risk profile

  • 3


    As subscriber, get monthly newsletter

  • 4


    Just update portfolio once a month

Stock Newsletters

Logo Transparent 200x77-Yukon GoldBiotechnology or Biotechs has been one of the best performing sectors over the past 10 years, with stock returns far outpacing the broader market. The model portfolio is a high-risk and high-reward one, focused on a highly promising sector, and continues to outperform key benchmark indexes consistently and convincingly.


The Graycell Smallcap Portfolio is a model-driven product focusing on the smallcap segment, with market cap ranging from $200 million - $3 billion. With a publishing history of over 10 years, the stock portfolio has delivered solid & consistent gains. This is a high-risk, high-reward product, providing focused exposure to a dynamic market segment.

More on Newsletters

Graycell Advisors, and its affiliates, officers, employees, families, and all other related parties, collectively referred to as ‘Graycell’ and/or ‘we,’ is a publisher of financial information, such as the Smallcap, and Prudent Biotech newsletters. We are not a Registered Investment Advisor (RIA). Historical performance figures provided are hypothetical and unaudited, and based on our proprietary analysis and system performance, back-tested over an extended period of time. Hypothetical or simulated performance results have limitations, and unlike an actual performance record, simulated results do not represent actual trading and consequently do not involve financial risk of actual trading. The performance results obtained are intended for illustrative purposes only. No representation is being made that an account will or is likely to achieve profit or losses similar to those shown. Past performance is not indicative of future results, which may vary. All stock and related investments have a degree of risk, which can result in a significant or total loss. In addition, biotech sector and smallcaps are characterized by much higher risk and volatility than the general stock market. Information contained herein is general and does not constitute a personal recommendation or takes into account the particular investment objectives, financial situations, or needs of individual investors. If you decide to invest in any of the stocks of the companies mentioned in the newsletters, samples, alerts, etc., sent to you or available on our websites, you can and may lose some or all of your investment. You alone are responsible for your investment decisions. Use of the information herein is at one's own risk. We are simply sharing the results of our model. Nothing should be construed as a recommendation or an offer to buy or sell any securities, and we are not liable nor do we assume any liability or responsibility for losses incurred as a result of any information provided or not provided or not made available in a timely manner, herein or on our website or using any other medium. We cannot guarantee the accuracy and completeness of any information furnished by us. We may or may not have existing positions in the stocks mentioned in our reports. Our models are proprietary and/or licensed, and can be changed or revised based on our discretion at any time without any notification. Subscribers and investors should always conduct their own due diligence with any potential investment, and consider obtaining professional advice before making an investment decision.
© Graycell Advisors. All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the written permission of Graycell Advisors is strictly prohibited and shall be deemed to be copyright infringement.